Anticoagulation in Patients with Liver Cirrhosis (Literature Review)

Liver cirrhosis is accompanied by complex hemostatic disorders with an increase in the risk of both hemorrhagic and thrombotic complications. Reduced coagulation protein synthesis, such as factors II, VII, IX, X and thrombocytopenia are associated with an increased risk of bleeding. Reducing the syn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	E. S. Eniseeva
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2019
Materias:	liver cirrhosis thrombosis thromboembolism anticoagulants Science Q
Acceso en línea:	https://doaj.org/article/680113dee029432296e257b044e2d1e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:680113dee029432296e257b044e2d1e4
record_format	dspace
spelling	oai:doaj.org-article:680113dee029432296e257b044e2d1e42021-11-23T06:14:42ZAnticoagulation in Patients with Liver Cirrhosis (Literature Review)2541-94202587-959610.29413/ABS.2019-4.2.3https://doaj.org/article/680113dee029432296e257b044e2d1e42019-05-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/2041https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Liver cirrhosis is accompanied by complex hemostatic disorders with an increase in the risk of both hemorrhagic and thrombotic complications. Reduced coagulation protein synthesis, such as factors II, VII, IX, X and thrombocytopenia are associated with an increased risk of bleeding. Reducing the synthesis of such anticoagulants as protein C, protein S, antithrombin III is accompanied by increased generation of thrombin, which leads to procoagulant status, increased risk of venous thrombosis, pulmonary embolism, and portal vein thrombosis. Activation of the coagulation cascade increases the risk of thrombosis, and also plays an important role in liver damage, contributing to the progression of fibrosis. Cirrhosis increases the risk of thromboembolic complications of atrial fibrillation.Anticoagulants are necessary for the prevention of thrombosis and thromboembolic complications. However, there are no large prospective studies. There is insufficient data on the safety of anticoagulant therapy in cirrhosis. There are difficulties in monitoring anticoagulation in the application of vitamin K antagonists and low molecular weight heparins.The review presents the available data on the use of warfarin, unfractionated heparin, low molecular weight heparins and direct oral anticoagulants in patients with liver cirrhosis, indicating the need for prevention of venous thrombosis in patients with risk factors, the possibility of preventing decompensation of cirrhosis, reducing the frequency of cardioembolic strokes in patients with atrial fibrillation.E. S. EniseevaScientific Сentre for Family Health and Human Reproduction Problemsarticleliver cirrhosisthrombosisthromboembolismanticoagulantsScienceQRUActa Biomedica Scientifica, Vol 4, Iss 2, Pp 23-28 (2019)
institution	DOAJ
collection	DOAJ
language	RU
topic	liver cirrhosis thrombosis thromboembolism anticoagulants Science Q
spellingShingle	liver cirrhosis thrombosis thromboembolism anticoagulants Science Q E. S. Eniseeva Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
description	Liver cirrhosis is accompanied by complex hemostatic disorders with an increase in the risk of both hemorrhagic and thrombotic complications. Reduced coagulation protein synthesis, such as factors II, VII, IX, X and thrombocytopenia are associated with an increased risk of bleeding. Reducing the synthesis of such anticoagulants as protein C, protein S, antithrombin III is accompanied by increased generation of thrombin, which leads to procoagulant status, increased risk of venous thrombosis, pulmonary embolism, and portal vein thrombosis. Activation of the coagulation cascade increases the risk of thrombosis, and also plays an important role in liver damage, contributing to the progression of fibrosis. Cirrhosis increases the risk of thromboembolic complications of atrial fibrillation.Anticoagulants are necessary for the prevention of thrombosis and thromboembolic complications. However, there are no large prospective studies. There is insufficient data on the safety of anticoagulant therapy in cirrhosis. There are difficulties in monitoring anticoagulation in the application of vitamin K antagonists and low molecular weight heparins.The review presents the available data on the use of warfarin, unfractionated heparin, low molecular weight heparins and direct oral anticoagulants in patients with liver cirrhosis, indicating the need for prevention of venous thrombosis in patients with risk factors, the possibility of preventing decompensation of cirrhosis, reducing the frequency of cardioembolic strokes in patients with atrial fibrillation.
format	article
author	E. S. Eniseeva
author_facet	E. S. Eniseeva
author_sort	E. S. Eniseeva
title	Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
title_short	Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
title_full	Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
title_fullStr	Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
title_full_unstemmed	Anticoagulation in Patients with Liver Cirrhosis (Literature Review)
title_sort	anticoagulation in patients with liver cirrhosis (literature review)
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2019
url	https://doaj.org/article/680113dee029432296e257b044e2d1e4
work_keys_str_mv	AT eseniseeva anticoagulationinpatientswithlivercirrhosisliteraturereview
_version_	1718416948784529408

Anticoagulation in Patients with Liver Cirrhosis (Literature Review)

Ejemplares similares